Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) COO Yvonne Greenstreet sold 11,236 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $161.00, for a total transaction of $1,808,996.00. Following the completion of the transaction, the chief operating officer now owns 15,759 shares of the company’s stock, valued at $2,537,199. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Yvonne Greenstreet also recently made the following trade(s):
- On Tuesday, May 5th, Yvonne Greenstreet sold 7,811 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $140.00, for a total transaction of $1,093,540.00.
Shares of NASDAQ ALNY opened at $162.25 on Monday. The company has a market capitalization of $18.72 billion, a P/E ratio of -20.21 and a beta of 1.86. Alnylam Pharmaceuticals, Inc. has a 52-week low of $69.11 and a 52-week high of $164.09. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.48 and a current ratio of 4.68. The company’s 50 day moving average price is $141.28 and its 200-day moving average price is $126.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.89) by $0.27. The firm had revenue of $71.94 million for the quarter, compared to the consensus estimate of $90.45 million. Alnylam Pharmaceuticals had a negative net margin of 310.01% and a negative return on equity of 57.63%. The company’s revenue for the quarter was up 173.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.42) EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.17 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $28,000. Sunbelt Securities Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $9,358,000. Exchange Traded Concepts LLC raised its holdings in Alnylam Pharmaceuticals by 84.1% during the first quarter. Exchange Traded Concepts LLC now owns 707 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 323 shares during the last quarter. Advisor Group Holdings Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $159,000. Finally, Boston Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $202,000. Institutional investors own 93.42% of the company’s stock.
ALNY has been the subject of several analyst reports. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $111.00 to $122.00 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Nomura Securities decreased their price target on shares of Alnylam Pharmaceuticals from $75.00 to $74.00 and set a “reduce” rating on the stock in a report on Tuesday, April 14th. Evercore ISI started coverage on shares of Alnylam Pharmaceuticals in a report on Friday, April 24th. They set a “buy” rating and a $160.00 price target on the stock. Oppenheimer lifted their price target on shares of Alnylam Pharmaceuticals from $140.00 to $162.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $148.00 to $162.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $148.47.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Recommended Story: What are the benefits of investing in REITs?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.